Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Daniel E. Freedberg, Joseph Conigliaro, Magdalena E. Sobieszczyk, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 22

Showing 22 citing articles:

Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Dimple Chakravarty, Sujit S. Nair, Nada Hammouda, et al.
Communications Biology (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 141
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Tobias Janowitz, Eva Gablenz, David Pattinson, et al.
Gut (2020) Vol. 69, Iss. 9, pp. 1592-1597
Open Access | Times Cited: 136
Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative against SARS-CoV2: An In Silico Analysis
Joseph T. Ortega, María Luisa Serrano, Beata Jastrzȩbska
Biomolecules (2020) Vol. 10, Iss. 6, pp. 954-954
Open Access | Times Cited: 55
Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2
Parth Sarthi Sen Gupta, Satyaranjan Biswal, Dipankar Singha, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 14, pp. 5327-5333
Closed Access | Times Cited: 37
Drugs being tested against covid-19 to slow down its spread and find effective treatment: A systematic review.
Arsalan Rasheed, Μalaika Νοοr, Τahir Usman, et al.
INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR) (2022) Vol. 10, Iss. 2, pp. 255-272
Open Access | Times Cited: 20
Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients
Carolina Lucas, Patrick Wong, Jon Klein, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 29
SARS-CoV-2 therapeutics: how far do we stand from a remedy?
Anurag Singh, Vandana Gupta
Pharmacological Reports (2021) Vol. 73, Iss. 3, pp. 750-768
Open Access | Times Cited: 22
Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19
Fatah Chérifi, Fatima Laraba‐Djebari
The Protein Journal (2021) Vol. 40, Iss. 6, pp. 799-841
Open Access | Times Cited: 19
COVID-19 Pandemic: current Challenges and future Perspectives
Sameh Saber, Ahmed E. Khodir, Abdalkareem Omar Maghmomeh, et al.
Research Journal of Pharmacy and Technology (2022), pp. 329-337
Closed Access | Times Cited: 12
Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus?
Amarnath Sen
Medical Hypotheses (2020) Vol. 144, pp. 110208-110208
Open Access | Times Cited: 18
Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects
Dihia Meghnem, Sharon A. Oldford, Ian D. Haidl, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 13
Repurposing Known Drugs as Covalent and Non-Covalent Inhibitors of the SARS-CoV-2 Papain-like Protease
Pietro Delre, Fabiana Caporuscio, Michele Saviano, et al.
(2020)
Closed Access | Times Cited: 4
"The Cytotoxicity of Metformin and Misoprostol Overwhelms their Antiviral Activity in SARS-CoV-2-Infected Vero-E6 Cell Culture"
Sherine Abdelmissih
Biomedical Journal of Scientific & Technical Research (2023) Vol. 52, Iss. 4
Open Access | Times Cited: 1
Famotidina en el tratamiento de pacientes hospitalizados con COVID-19. Revisión sistemática y metaanálisis
John S. Paisig Rosas, Alex N. Castañeda Sabogal
Revista chilena de infectología (2024) Vol. 41, Iss. 1, pp. 7-19
Open Access
Molecular Mechanism of Clinically Oriented Drug Famotidine with the Identified Potential Target of SARS-CoV-2
Parth Sarthi Sen Gupta, Satyaranjan Biswal, Dipankar Singha, et al.
(2020)
Closed Access | Times Cited: 2
Repurposing Prolactin as a Promising Immunomodulator for the Treatment of COVID-19: Are Common Antiemetics the Wonder Drug to Fight Coronavirus?
Amarnath Sen
(2020)
Open Access | Times Cited: 2
Corona Virus: Commonly Followed Treatment Regimen, an Updated Follow-Up on Trending Perspectives
Rashmi Saxena Pal
Biomedical Journal of Scientific & Technical Research (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 2
Molecular Mechanism of Clinically Oriented Drug Famotidine with the Identified Potential Target of SARS-CoV-2
Parth Sarthi Sen Gupta, Satyaranjan Biswal, Dipankar Singha, et al.
(2020)
Closed Access | Times Cited: 1
The Efficacy of Famotidine in Improvement of Outcomes in Hospitalized COVID-19 Patients: A Phase III Randomized Clinical Trial
Hamid Reza Samimagham, Mehdi Hassani Azad, Mohsen Arabi, et al.
Journal of Research in Applied and Basic Medical Sciences (2022) Vol. 8, Iss. 2, pp. 75-82
Open Access | Times Cited: 1
Repurposing Known Drugs as Covalent and Non-Covalent Inhibitors of the SARS-CoV-2 Papain-like Protease
Pietro Delre, Fabiana Caporuscio, Michele Saviano, et al.
(2020)
Closed Access
Effective treatment regimen Famotidine with low molecular weight heparin (sodium enoxaparin) severe stages patients COVID-19
S Serafimov
(2020)
Open Access

Rashmi Saxena Pal, Yogendra Pal, Pranay Wal, et al.
Biomedical Journal of Scientific & Technical Research (2021) Vol. 34, Iss. 4
Open Access
Page 1

Scroll to top